After Rough Patch,Gilead Shouldn't Succumb to Deal Pressure

The struggling biotech giant shouldn’t abandon its strategy in the face of bad news

from WSJ.com: Markets http://ift.tt/2gmLzaE
via https://ifttt.com/ IFTTT